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ABSTRACT
Extracellular vesicles (EVs) have been showcased as auspicious candidates for delivering thera-
peutic cargo, including oncolytic viruses for cancer treatment. Delivery of oncolytic viruses in EVs
could provide considerable advantages, hiding the viruses from the immune system and provid-
ing alternative entry pathways into cancer cells. Here we describe the formation and viral cargo of
EVs secreted by cancer cells infected with an oncolytic adenovirus (IEVs, infected cell-derived EVs)
as a function of time after infection. IEVs were secreted already before the lytic release of virions
and their structure resembled normally secreted EVs, suggesting that they were not just apopto-
tic fragments of infected cells. IEVs were able to carry the viral genome and induce infection in
other cancer cells. As such, the role of EVs in the life cycle of adenoviruses may be an important
part of a successful infection and may also be harnessed for cancer- and gene therapy.
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Cells secrete small membranous particles termed extra-
cellular vesicles (EVs) into their environment with a
plethora of biological activities, including cell-to-cell
communication and disposal of harmful molecules
[1,2]. As EVs are emerging as a novel mode of inter-
cellular cargo delivery, increasingly more roles have
become associated with them in health and disease.
Viral infection of the host cells has been shown to
alter the EVs they secrete, which we refer to as infected
cell-derived EVs (IEVs) in this article. These IEVs can
carry stress signals and molecules of viral origin that
may facilitate or even directly mediate the spread of the
infection [3–10]. Previous work on EVs and viruses has
mostly focused on enveloped viruses, such as Epstein-
Barr viruses, HIV, hepatitis B virus and others [3,5,8–
13]. Certain enveloped viruses are known to use
mechanisms similar to the EV biogenesis for the pro-
duction of new virions from infected cells [5,14]. This
has led to the hypothesis that these viruses may hijack
the EV secretion pathway for the purpose of creating
viral particles resembling EVs, undetectable by the host
immune system [15]. IEVs have also been shown to
play roles in the dispersal and possibly pathogenesis of
non-enveloped virusus of the Picornaviridae and
Reoviridae families [16–21]. IEVs carrying these viruses
(either whole virions or viral RNA) are somethimes
referred as “quasi-enveloped viruses” and they can
target immune cells in addition to their common
hosts, hence assisting the virus to evade immune
responses [22].
Viruses have emerged as therapeutic tools in gene-
and cancer therapy due to their efficiency in delivering
cargo to target cells. Yet, they are susceptible to eradi-
cation by the immune system and/or may cause a
severe immune response. As such, reducing the nega-
tive effects of immunity may play a crucial step in the
advancement of viral therapeutics. To achieve this,
IEVs could be utilized to protect the virus from the
immune system [23,24]. Furthermore, like EVs, IEV-
hidden viruses could be more specific in targeting
certain tissues [25–29] and acquire multiple entry path-
ways into the targeted cells [30–34]. Recent studies
have shown that IEVs carrying oncolytic adenoviruses
(Ad) could be used as novel therapeutics for the
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treatment of cancer [23,35] and that IEVs carrying
adeno-associated viruses (AAV) may serve as enhanced
tools for gene therapy [24,36,37]. In the present work,
we compared IEVs secreted by PC-3 prostate- and
A549 lung cancer cells infected with an oncolytic Ad,
Ad5/3-D24-GMCSF [38], to the control EVs (cEVs)
secreted by the non-infected cancer cells (cEVs). We
found that, while cEVs and IEVs were strikingly similar
in almost every aspect investigated, the major differ-
ence between the two populations was the increased
viral cargo in the IEVs as the infection progressed.
Importantly, these IEVs were able to infect other, auto-
logous cancer cells. The IEVs were produced already at
the early phase of the infection, when the cells’ viability
had not yet been compromised, suggesting that Ad
may transmit infection via IEVs even prior to the
lytic release of viruses. These results indicate that in
addition to the Ad capsid, IEVs provide an alternative
vector for the viral genome.
Results
IEVs are secreted by infected cells both at the early
and late stages of infection
To investigate whether cancer cells could secrete infec-
tive IEVs, the cells were infected with Ad5/3-D24-
GMCSF virus and the cell-conditioned medium
(CCM) containing the IEVs was collected after a cyto-
pathic effect was observed under the microscope. Ad5/
3-D24-GMCSF is an oncolytic serotype Ad5 virus
expressing an Ad3 fibre knob for enhanced uptake
and granulocyte-macrophage colony-stimulating factor
(GMCSF), which is used to promote the antitumor
immune response [38]. For separating the IEVs from
free Ad in the cell culture medium, we sought to take
advantage of their differences in density. Ad have a
reported density of approximately 1.21 g/mL in iodix-
anol [39], while EVs have been reported to be lighter:
approximately 1.01–1.20 g/mL, depending on their
source [40,41]. After fractionation with the iodixanol
gradient, cytotoxic fractions were identified by viability
assay and examined by cryo-transmission electron
microscopy (cryo-TEM) (Figure 1). Initially, a top-
loaded sucrose density gradient with a differential cen-
trifugation protocol was applied and fractions were
analysed for cytotoxicity and distributions of small
particles, total protein and viral cargo (Supplementary
Figure 1). However, due to the presence of impurities
and inadequate separation of IEVs from free viruses as
shown by cryo-TEM imaging (Supplementary Figure
2), a bottom-loaded iodixanol gradient was employed.
Fractionation with free virions purified from infected
cells was inspected in order to identify the fractions
they occupy (Figure 1(a)). As expected, fractions with a
density of 1.21 g/mL or heavier in the iodixanol gra-
dient (fractions 7–10) were found to possess a clear
cytotoxic effect, confirming the presence of free virions.
For cryo-TEM imaging, samples were collected after
five days from the initiation of infection and IEV frac-
tions 3–5 were pooled together as they were identified
as the most cytotoxic ones and had a lighter density
than the fractions containing the free virus. cEVs were
not found to be cytotoxic, instead they had a viability
increasing effect (Supplementary Figure 1D and E),
consistent with our previous results [42]. Detailed mor-
phological imaging of IEVs by cryo-TEM did not
reveal any differences between the vesicles from Ad-
infected PC-3 and A549 cells or cEVs (Figure 1(c,d);
Supplementary Figure 1). IEVs from both cell lines
were highly heterogeneous regarding their size, shape
and electron density, consistent with earlier reports and
characteristic of EVs regardless of their source [43,44].
Most of the vesicles had a spherical shape, while few
were also observed to havefused, multivesicular or
completely irregular shapes. Additionally, a higher
electron density in some of the vesicles indicated a
higher concentration of proteins or other biomolecules
inside. In light of a previous report by Ran et al. [23]
describing infective extracellular microparticles, we
used cryo-TEM imaging to further analyse the pellet
of cell debris that was produced during IEV purifica-
tion by centrifugation at 15,000 g (Figure 1(e,f)). These
samples were found to contain large membrane frag-
ments, free virions and vesicles of various sizes resem-
bling the IEVs purified with iodixanol density gradient.
Additionally, a single, large membrane structure was
identified containing an apparently intact virion and
capsid fragments, presented in Figure 1e. This is simi-
lar to what Ran et al. had described earlier, but no
other such structures or vesicles containing virions
were found in the studied samples.
Samples were also collected every 24 hours after
the initial infection (samples day (D) D1–D5) to
determine when the first infective IEVs were secreted
(Figure 2(a,b)). Since some of the IEVs could be
derived from infected, dying cells, and their cytotoxi-
city could be explained by other cytotoxic cargo,
such as apoptosis promoters or Ad death protein,
we also assessed whether the IEVs could actually
infect cells with the viral DNA. For this, cells were
treated with D1 or D3 IEVs and TEM was used to
inspect for the presence of virions forming in the
nuclei of IEV treated cells. Indeed, after incubation
with the D1 and D3 IEV samples, virions could be
seen in the nuclei of both PC-3 and A549 cells
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(Figure 2c–e), demonstrating that IEVs can act as
conveyers of Ad infection. Remarkably, the cytotoxic
effect in the IEV fractions appeared already in D1
samples, collected only 24 hours after the infection.
At this stage, the cells did not yet display any signs
of cell death (Figure 3(a)), which is considered a
prerequisite for Ad release [45,46]. In the subsequent
samples from D2, the cells began to display signs of
Figure 1. Cryo-TEM imaging of cEVs and IEVs isolated with an iodixanol gradient. (a) To identify the fractions containing free Ad
virions, purified virions were loaded into the iodxianol gradient and separated into 10 fractions. A549 cells were incubated for
72 hours with equal volumes of each fraction from the gradient. Based on their cytotoxicity, fractions 7–10 were found to contain
virions. (b) Gravimetrically determined densities of the different fractions. (c and d) IEV samples were collected five days after the
initial infection and fractions 3–5 that were found to be cytotoxic, were pooled together for imaging. All vesicles displayed similar,
heterogenous structures regardless of origin (c: PC-3 and d: A549). Representative images of IEVs from three individually prepared
samples from both cell lines are presented, with 41 A549 IEVs and 98 PC-3 IEVs identified and analysed from 178 and 179 images,
respectively. (e and f) The pellets resulting from the initial centrifugation at 15,000 g of the infected CCM (e: PC-3, f: A549) were also
imaged by cryo-TEM. In addition to vesicles similar to those detected in c and d, intact virions (red arrow) and large cellular debris
were observed. 152 images were analysed in e, and 60 images in f. In a, statistical significance was assessed using one-way ANOVA
with Tukey’s HSD post hoc test and denoted by grouping with letters: for all variables with the same letter, the difference between
the means is not statistically significant.
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early apoptosis, including cell rounding and nuclear
condensation [47], which progressed up to D5, when
virtually all of the cells had died and become
detached from the surface. The D1 samples from
the PC-3 cells appeared to be less cytotoxic than
the samples from D2 to D5. This may be related to
the observation that, compared to A549 cells, fewer
PC-3 cells began to express the viral hexon protein at
Figure 2. IEVs separated from free virions are able to infect cells. (a and b) The iodixanol gradient purification of IEVs was performed
for samples produced at different time points after the initial infection of the cells. Cytotoxicity of the 10 fractions was assessed
using the sample originating cell lines as the recipients. In addition to the free virus containing fractions, also lighter fractions 2–6,
corresponding to the fractions where IEVs, were found cytotoxic. (c–e) In order to clarify, whether IEVs could induce the formation
of new viruses in recipient cells, the cells were incubated with an autologous IEV fraction 4 of D1 and D3 and imaged using TEM. In
both cell lines (c: A549 after 48 h with IEV fraction D3, d: PC-3 after 24 h with IEV fraction D3 and e: A549 after 48 h with IEV fraction
D1), viruses (red arrows) were found in the nuclei of the treated cells. The nuclear membrane is shown in the images with a white
arrowhead. In a and b, the median viability compared to the untreated control cells is presented with individual results, with sample
size N = 3. Statistical significance was assessed with one-way ANOVA with Tukey’s HSD post hoc test in a and b, and denoted by
grouping with letters: for all variables with the same letter, the difference between the means is not statistically significant. If two
variables have different letters, they are significantly different. Uppercase letters denote fractions of the same time point while
lower case letters denote different time points of each fraction. Additionally, statistically significant difference to the non-treated
control samples is denoted with an asterisk. p-values of statistically differing samples are listed in Supplementary Figure 5.
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D1, as indicated by the immunofluorescence staining
of the viral coat protein in the infected cells (Figure
3(b)). Thus, the amount of D1 IEVs and their viral
cargo may be smaller, hence resulting in a less cyto-
toxic effect in comparison to the later time points
and A549 derived D1 IEVs.
Even with density gradient purification, virions
could be co-purifying with the IEVs by association to
their surface during isolation. To assess this, the
samples were tested for detergent resistance. Triton
X-100 is commonly used for isolating Ad from infected
cells, as the detergent lyses all cellular membrane struc-
tures, including EVs [48], retaining the Ad intact. The
IEV samples and control virions were treated with
Triton-X 100 and ultracentrifuged on top of an iodix-
anol cushion to separate any surviving virions from the
detergent and the pellets were tested for cytotoxicity
(Figure 4(a)). As expected, Ad virions were found to be
Figure 3. IEV producing cells start to show signs of apoptosis after two days from the initial infection. (a) A549 and PC-3 cells were
infected with the Ad and their viability was assessed by inspection of cell morphology (transmitted light) and staining with Hoechst
3342 (Hoechst, blue) for nuclear condensation and propidium iodide (PI, red) for membrane permeability every 24 hours after the
initial infection. At D1, based on nuclear staining and cell morphologies, no clear difference was found compared to the control
cells, while cells from D2 to D5 started to show an in increase in cell rounding, nuclear condensation (bright, fragmented nuclei) and
membrane permeability (PI positive). (b) Immunofluorescence staining of Ad hexon coat protein in the cells showed that a larger
population of A549 than PC-3 cells expressed the viral protein at D1. Regarding cell death and hexon-positively stained cells, the
outcome was the same for both cell lines by D3, when most cells were found to be dead or dying. Representative images of results
are shown (three independent experiments in a and two in b).
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resistant to the treatment with no significant effect on
their cytotoxicity. IEVs on the other hand, lost their
cytotoxic effect after the treatment, and thus their
infectivity could not be explained by the presence of
virions, with the exception of A549 D5 samples, which
retained a significant portion of their cytotoxicity.
Figure 4. IEVs are sensitive to detergent treatment and Ad neutralizing antibody. (a) Detergent treatment. IEVs and Ad controls
(Ad1: 5 × 108 particles, Ad2: 5 × 109 particles) were treated with 0.1% (w/v) Triton X-100 (circles), purified by ultracentrifugation and
their cytotoxicity towards autologous cells was assessed, along with non-treated samples (squares). Free virions resulted in 65–90%
loss of viability. In contrast to free virions, IEVs lost their cytotoxicity by the detergent treatment, with the exception of D5 A549
samples, which retained some of their effect. (b) The susceptibility of IEVs and Ad controls to Ad neutralizing antibody. Samples
were treated with an Ad neutralizing antibody for one hour (circles) and their cytotoxicity towards autologous cells was assessed,
along with non-treated samples (squares). As with Ad controls, IEVs lost their cytotoxicity after the antibody treatment. Results with
individual samples are presented, with statistical significance assessed using paired two tailed Student’s t-test comparing cell
viability values of each sample pair without and after treatment. Results with Ad controls from both cell lines were analysed
together. Significant differences between non-treated and treated samples are denoted with asterisks: *: p < 0.05, **: p < 0.01 and
***: p < 0.001. p-values of statistically differing samples are listed in the Supplementary Figure 6.
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Additionally, it was assessed, whether IEVs are resis-
tant to Ad neutralizing antibodies (Figure 4(b)). This
should be the case if the IEVs are encasing infective
viral components. However, it was found that IEVs are
completely inactivated by the antibody just like free
virions, suggesting that while they may not contain
intact virions, the infectivity of IEVs is dependent on
Ad proteins and that those proteins are on the outer
surface of IEVs.
IEVs are structurally similar to normal EVs
Next, the IEV fractions were screened with nanoparticle
tracking analysis (NTA) to estimate the concentration of
particles and their size distributions combined with a total
protein assay (Figure 5(a,b); Supplementary Figures 2G
and 3G). Particles ranging from 50 to 500 nm from both
infected and non-infected cell cultures were found to be
enriched in the top fractions 1–6, corresponding to densi-
ties of 1.014–1.174 g/mL, with a peak of IEV numbers at
fractions 3 and 4. The protein per particle ratio calculated
for each IEV fraction showed consistent values of 1–2 mg
10−13 particles in fractions 1–4 of PC-3 derived EV/IEV
samples from each day and approximately 2–5mg 10−13 in
fractions 5 and 6 (Figure 4(e,f)). Analysis of the particle size
distributions fromall fractions revealed that IEVswere very
similar in size to cEVs with increasing size along the pro-
gress of infection, with representative size distributions of
fraction 4 presented in Figure 5(g,h). Some variation in size
was also observed as a function of density (Supplementary
Figures 3 and 4), with larger particles present in fractions 3
and 4 than in others. Vesicles of similar size were also
observed in the cryo-TEM images from both cell lines
(Figure 1), demonstrating that the particles analysed by
NTA were indeed vesicles. Variation in the amount of
particles isolated from both cell lines at different time
points is presented in Figure 6, with combined particle
yields from fractions 1–6 and fractions 7–10 separately.
With PC-3 samples, the median IEV yields seemed to
increase as the infection progressed until dropping at D5,
while in A549 samples the median IEV yields increased
afterD2 and remained stable until D5. In fractions 7–10 the
median particle yields seemed to increase through D1–D5
with both cell lines.
To investigate how the infection of the cells is reflected
in the total IEV population they secrete, the expression of
some of the ubiquitous EV proteins (Hsp70, TSG101, CD9
and CD81) along with α-tubulin representing a cellular
housekeeping protein and GM130, a protein of the golgi
apparatus, were assessed by western blot analysis from
pooled fractions 1–6. These were compared to their respec-
tive cell lysates (Figure 7(a,b)). In general, compared to the
cell lysates, IEVs and cEVs contained fewer soluble proteins
and were enriched in the membrane proteins CD9 and
CD81. Out of the soluble proteins, Hsp70 and TSG101
were the most prominently expressed in IEVs and cEVs,
though TSG101 staining showed only very weak or unde-
tectable bands in A549 samples. There was significant
variation between the expressions of different proteinmar-
kers between samples D1 and D5. cEV and D1 samples
seemed to contain very low levels of any of the proteins
analysed, while IEVs from later time points were more
prominent. In PC-3 samples, D2–D4 produced the stron-
gest bands of the EV associated proteins Hsp70, TSG101,
CD9 and CD81, while in the A549 D2–D4 samples the
band intensities contained less variation, with an increase
of Hsp70 in D4 andD5 and CD9 in D5 IEVs. D3–D5 IEVs
from both cell lines also showed very faint bands of
GM130, suggesting the presence of vesicles from apoptotic
cells in those samples, since golgi proteins are not normally
associated with EVs. The cell lysates showed reduction in
the expression of virtually all of the analysed protein mar-
kers, except for Hsp70, which was expressed more when
compared to α-tubulin. The expression of membrane pro-
teins in the cell lysates however seemed to be increased due
to the infection, especially CD9 in A549 and CD81 in PC-3
as they were undetectable in the control cells. The heavier
fractions 7–10 that were excluded from the IEV pools were
also analysed for the same markers, showing little to no
proteins in D1 and D2 samples, but D3–D5 contained
bands frommost of the markers, including also prominent
GM130 bands. This suggests for the presence of cellular
debris in the samples.
In addition to the western blot analysis of these
markers, the overall protein size profile of the samples
was assessed by SDS-PAGE (Figure 7(c,d)). While the
cell lysates contained a more diverse distribution of
differently sized proteins, the staining patterns of the
cEV and IEV samples from both cell lines showed
intense smeared bands between the 100 and 55 kDa
markers as well another sharper band of approximately
25 kDa. While these patterns might be typical to EVs,
samples of fractions 7–10 showed a similar pattern,
suggesting that it is not strictly EV-specific. In addi-
tion, a band of approximately 130 kDa appeared in the
samples after the infection, corresponding to the Ad
hexon protein, with its intensity increasing in the IEV
and Fr.7–10 samples over the progression of the
infection.
IEVs carry viral DNA and proteins reflecting the
stage of infection
To evaluate the differences regarding the viral load
between the IEVs secreted at different stages of the
infection (D1–D5), the expression of viral proteins
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Figure 5. IEVs and control EVs have similar sizes and a density dependent protein content. The particle concentrations (a and b)
were measured from each fraction of IEV and cEV samples and presented as relative concentrations compared to the other fractions
of each sample. All of the samples showed a peak in particle concentration at fractions 3 and 4, corresponding to the IEVs and cEVs.
In cEV preparations, the particle was more significant due to the longer production time. (c and d) Protein per particle ratios were
calculated using total protein and particle concentrations for each IEV and cEV fraction. These values were found to be consistent
across D1–D5. Although the denser fractions seemed to have a higher value, there were no statistically significant differences due to
the small sample size. The size distribution of fraction 4 from each sample (e and f) is presented as a representative fraction of the
IEVs and cEVs. The median particle diameter was 100–150 nm in each sample, with the mean size growing at later time points.
Additional size distributions for fractions 1–6 presented in Supplementary Figures 2 and 3 together with the total protein
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and viral DNA (Figure 8) were assessed from each
fraction. At almost all of the time points, fractions 7–
10, containing the free virus, harboured more hexon
protein (Figure 8(a,b)) and viral DNA (Figure 8(c,d))
than the IEV fractions. D1 and D2 IEVs showed also
much lower or undetectable amounts of Ad hexon
protein compared to D3–D5. The peak in hexon con-
centrations in IEVs appeared to follow the same pat-
tern as particle concentrations (Figure 5(a,b)), with an
apparent peak in fraction 4. The D1 samples contained
much less hexon protein and DNA in the free virus
fractions than at the later time points. This is in line
with the observation that the cells had not yet been
lysed and thus released the virions (Figure 3a), suggest-
ing that the hexon protein and DNA in D1 fractions 7–
10 was from residual viruses left from the initial infec-
tion. At later time points (D3 and D5), the amount of
DNA and hexon protein in the fractions 7–10 was
significantly higher than in the IEV fractions 1–6,
indicating the release of viruses from the cells and
correlating with evident cytopathic effects. The amount
of viral DNA per particle in the IEV fractions
depended on the cell line, fraction density and isolation
time point. The heaviest D3 and D5 PC-3 IEV fractions
contained the most DNA per particle (Figure 8(e,f)).
These results indicate that the progression of the infec-
tion is reflected on the viral cargo of IEVs as well, with
a dramatic increase at D3 in the amount of viral pro-
teins when the cells are dying.
Further characterization of the viral cargo in IEVs
is provided in Figures 9 and 10. For assessing indi-
vidual Ad proteins, western blot analysis of the viral
proteins in pooled IEV fractions (1–6) and cell
lysates was performed with a polyclonal anti-Ad
antibody (Figure 9(a,b)). In line with the dot blot
analysis of the hexon protein, the amount of other
viral proteins increased with time in the IEVs and in
the cell lysates when compared to α-tubulin. In con-
trast to the cell lysates, the IEVs seemed to contain
more of the large (>100 kDa) Ad protein bands
corresponding to the hexon protein (108 kDa),
while the cell lysates were more enriched in Ad
proteins under 70 kDa, corresponding to Ad penton
proteins (64 kDa) and protein V (42 kDa). The topo-
logical arrangement of Ad proteins on IEVs was also
examined by a dotblot analysis with proteinase K
(Figure 9(c,d)): samples from fractions 3–6 of time
points D1, D3 and D5 were treated with proteinase
K, cleaving any exposed proteins on the vesicle sur-
face, followed by heat inactivation of the enzyme and
dotblot analysis with the polyclonal anti-Ad anti-
body. Addition of Triton X-100 with proteinase K
was used to completely cleave all proteins in the
sample to estimate any non-specific binding caused
by the presence of inactive proteinase K. Compared
to samples without proteinase K treatment, the signal
intensity dropped 20–100% in all samples, with the
highest drops (approx. 75–100%) occurring in frac-
tions 5 and 6, suggesting that Ad proteins are more
exposed in these fractions, although fraction 4
usually had the highest overall intensity. Fractions 1
and 2 were also analysed, but they produced very
weak signals that could not be analysed reliably. A
control sample with purified free Ad virions resulted
in complete eradication of signal as Ad has no lipid
membrane to protect itself from the enzyme. PC-3
D1 samples also produced only a weak signal to
begin with, as the non-specific binding of antibodies
caused by the presence of proteinase K was stronger
than the in the samples without treatment themselves
(Figure 9(c)). As the proteinase K background signal
in the PC-3 D1 samples was nearly identical to the
detergent treated replicates, a complete removal of
proteins was estimated. Overall, these results demon-
strate that all of the IEV samples analysed contain
Ad proteins that are exposed outside the vesicles.
In addition to the Ad proteins, the amount of total
viral DNA in IEV pools was compared between D1, D3
and D5 samples (Figure 10(a)). In A549 samples, the
amount of viral DNA associated with the IEVs
increased on average by a factor of approximately
19.8 from D1 to D3 and by 14.9 from D3 to D5. In
PC-3 samples, the increase in viral DNA amount from
D1 to D3 was much higher, 338.4 on average, while
there was no significant change from D3 to D5. The
presence of a protective EV membrane around the viral
DNA against enzymatic degradation was also investi-
gated (Figure 10(b)). The IEVs were treated first with
proteinase K at +55°C to degrade any protective pro-
tein structures such as the viral capsid, followed by
distributions of each sample. For each sample, data is presented as medians with individual results, with N = 3 for each sample.
Statistical significance in a–d was assessed using one-way ANOVA with Tukey’s HSD post hoc test, denoted by grouping with letters:
for all variables with the same letter, the difference between the means is not statistically significant. If two variables have different
letters, they are significantly different. Uppercase letters denote fractions of the same time point while lower case letters denote
different time points of each fraction. p-values of statistically differing samples for particle and protein concentrations are listed in
the Supplementary Figures 7 and 8, respectively.
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cleaving of the exposed DNA with DNAse I. As a
control, we used purified viruses, which lost virtually
all DNA as a result of the treatment, with less than 1%
remaining. IEV samples retained on average approxi-
mately 5–20% of the viral DNA after the treatment.
While this was significantly more than in the free virus
control, a 80–95x loss in DNA still seemed drastic. Yet,
it could be explained by leaking from the IEVs due to
the proteinase K treatment or due to DNA binding to
the exterior side of the IEVs. Therefore, since EVs have
been reported to carry DNA from the secreting cells
[6,49–55], we sought to determine whether the loss in
cellular DNA in IEVs was similar to the viral DNA loss.
For this purpose, we chose to target the GAPDH-
encoding region, since it has been reported earlier to
be consistently present in EVs [49]. While the amount
of cellular DNA was much lower compared to viral
DNA, the resulting loss was comparable, suggesting
that they are both associated with the IEVs in a similar
manner. Additionally, treatment of IEVs with DNase I
without proteinase K resulted in a slightly less exten-
sive loss in DNA as observed with E4 DNA that was
tested, with an average loss of approximately 60–85%.
This indicates that Ad DNA is not leaking from inside
Figure 6. Particle yields increase as the infection progresses. (a and b) Total particle yields for each time point were calculated
separately for fractions 1–6 representing the IEVs, and fractions 7–10 containing free virions and large impurities. Total yields were
normalized across all time points of each experiment and are presented as relative particle yields, with individual yields (N = 3) and
their median for each time point. The overall trend was that particle yields increased along the progression of the infection,
although the variation between samples was high. Statistical significance was assessed using one-way ANOVA with Tukey’s HSD
post hoc test, denoted by grouping with letter: time point samples with no significant difference are given the same letter,
capitalized for fractions 1–6 and lower case for fractions 7–10. p-values of statistically differing samples are listed in the
Supplementary Figure 9.
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of the IEVs and that it is mostly unprotected by pro-
teins. During the optimization of the DNA cleaving
treatment, we found that Ad virions had to be treated
with proteinase K at +55°C to release their genomic
DNA (gDNA). While it has been reported that incuba-
tion of Ad virions at +55°C [56] or at pH 4–5 [57] in
itself would result in releasing their DNA, it seemed to
be an incomplete process. The treatment of the virions
at +55°C and pH 4–5 followed by proteinase K treat-
ment at +37°C and pH 7 was not sufficient to expose
the viral DNA, as it remained nearly completely pro-
tected from DNase-mediated cleavage. However, the
DNA in IEV samples was cleaved with equal efficiency
regardless of the treatment temperature, providing
further support to the possibility that the DNA in
IEVs is not protected by Ad capsids. Furthermore, the
samples contained nearly identical amounts of DNA of
Ad genes E1A and E4 posited at the opposite sections
of the Ad genome, suggesting that IEVs contain the
whole intact viral genome, instead of random
fragments.
Discussion
The results of this study demonstrate that IEVs, i.e.
EVs from Ad infected cells, carry viral DNA and pro-
teins in a manner that allows them to mediate the viral
infection to other cells. While this concept of infection
mediating IEVs has previously been presented by Ran
et al. [23], they focused on large fragments derived
from infected, dying cells that were proposed to enclose
intact Ad virions. Additionally, Maguire et al. [24]
showed that cells infected with AAV released infective
EVs containing AAV particles. Based on the present
data, we suggest that also another type of small,
secreted IEVs exists, which carry Ad cargo without an
intact capsid, but are still able to infect cells. The
physical properties, such as the size, density and mor-
phology of IEVs were almost identical to those of the
normal EVs, and IEVs were sensitive to detergent
treatment, to which intact Ad virions are resistant.
We were unable to detect any small IEVs containing
whole Ad particles in cryo-TEM, suggesting that those
vesicles were either rare, or they had a density similar
to the free Ad, and as such they were excluded from
our analyses of the lighter IEVs. We were also unable
to detect the large apoptotic vesicles carrying Ad par-
ticles reported by Ran et al. in our IEV preparations.
Most likely they were cleared away during our isolation
procedure with the large cell debris given their appear-
ance in those pellets, as shown by the cryo-TEM
images.
Previous work regarding quasi-enveloped viruses
has mainly focused on RNA-viruses. They are
assembled in the cytoplasm of the host cell [58,59],
whereas Ad particles are formed inside the infected
cell’s nucleus and are released by the lysis of the cell
[45,46]. Therefore, to be packed into IEVs, intact Ad
would have to escape the nucleus after assembly, but
prior to cell lysis. While this may be possible, a simpler
alternative would be that the infected cells direct viral
products (including DNA) to be secreted out from the
cell via the IEVs in the same manner to other (poten-
tially harmful) molecules [1,6]. This model also implies
an alternative mode of Ad DNA import into its sub-
cellular target, the nucleus, which is normally mediated
by the capsid [60]. Indeed, EVs have been reported to
deliver functional DNA into healthy cells as well
[52,61], suggesting that IEVs could act as a vector for
Ad DNA delivery. We also found that approximately
80–95% of the viral DNA was associated with the outer
surface of the IEVs and that they could be neutralized
with antibodies. Therefore, it is likely that their infec-
tivity is still dependent on the viral proteins exposed on
the outer surface of the IEVs and that the Ad DNA is
associated with the viral proteins. For example, the Ad
hexon protein has been shown to mediate the transport
of DNA into the nucleus after endocytosis, which could
be blocked by hexon-binding antibodies [62]. Similar
results regarding the localization of DNA on EVs has
been reported earlier as well [53–55], suggesting that it
may be a generally occurring feature of EVs, not lim-
ited only to cancerous cells. Taken together, there
appeared to be some correlation between cytotoxicity,
Ad DNA per particle ratio and Ad protein topology in
the different fractions, as fractions 5 and 6 displayed
highest values in all of these properties. This would
suggest that displaying the most Ad DNA and proteins
Figure 7. Characterization of the IEV protein cargo for EV markers. (a and b) Commonly EV-associated proteins Hsp70, TSG101, CD9
and CD81 along with GM130 and α-tubulin were analysed by western blotting from the pooled fractions 1–6 of cEVs and IEVs or cell
lysate (CL) of PC-3 (a) and A549 (b) cells. Also fractions 7–10 from IEV samples were analysed. Representative blots are shown with
three independent samples of IEVs/cEVs and two independent samples of CL and fractions 7–10. While other protein markers
seemed to be depleted from the IEVs and cEVs, membrane proteins CD9 and CD81 were enriched in those samples. (c and d) the
samples were also analysed by stain-free SDS-PAGE, showing a distinct pattern of proteins in both pools of fractions 1–6 and 7–10
when compared to CL.
12 H. SAARI ET AL.
Figure 8. Fraction- and time point -based comparisons of viral cargo in IEV fractions. (a and b) The amount of Ad hexon coat protein
was assessed from the IEV density gradient fractions D1 – D5 from PC-3 (a) and A549 (b) cell lines by dot blotting. Representative
blots are shown from two individual experiments. The intensity values were normalized by setting the highest intensity (usually D5
fr.8) to 100 a.u. (N = 2 for both cell lines). Data is presented as median values with individual results. Due to the low signal, D1
samples were omitted from the graphs. (c and d) The median amount of viral DNA and individual results of each IEV fraction from
D1, D3 and D5 are shown for each time point, normalized against the total DNA in the sample set and presented on a logarithmic
scale. (e and f) The Ad DNA concentration in d and e was compared to the particle concentrations derived from NTA analysis. Ad
DNA per particle values were calculated for each IEV fraction and are presented with individual results with their median on a
logarithmic scale. The results show two factors predicting higher DNA/particle values: fraction density and time from infection. All
qPCR measurements were performed with primers against Ad E4 gene. In a and b, N = 2 and in c and d, N = 3. Statistical
significance was assessed using one-way ANOVA with Tukey’s HSD post hoc test, denoted by grouping with letters: for all variables
with the same letter, the difference between the means is not statistically significant. If two variables have different letters, they are
significantly different. Uppercase letters denote fractions of the same time point while lower case letters denote different time
points of each fraction. p-values of statistically differing samples for hexon amounts and Ad DNA are listed in Supplementary Figures
10 and 11 respectively.




Figure 9. Viral proteins are expressed both on the exterior and interior of IEVs. (a and b) Ad proteins associated with PC-3 (a) and
A549 (b) IEVs and cell lysates (CL) were blotted with a polyclonal anti-Ad antibody. Western blots of α-tubulin are presented for
comparison as a housekeeping protein. Overall, the band intensities of Ad proteins increased along the progression of the infection
without changes in pattern, also in CLs when compared to α-tubulin. In contrast to CLs, IEVs were enriched in proteins of
approximately 130 and 110 kDa, corresponding to Ad hexon. (c and d) Dotblot assessment of Ad proteins on the surface of IEVs. IEV
fractions 3–6 from time points D1, D3 and D5 were treated with proteinase K to determine the relative loss of signal from polyclonal
anti-Ad antibody binding due to proteolytic cleaving of Ad proteins bound to the external surface of IEVs. A control with Triton X-
100 was also used with proteinase K to establish the background signal, when complete cleavage of samples had occurred. In all of
the samples, a reduction of signal was achieved with proteinase K treatment, with representative blots shown in c and the
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on the surface of IEVs would result in the highest
infectivity. As the intact Ad genome is a very large
molecule (26–46 kbp), its packing inside IEVs could
be structurally impossible, and therefore its binding via
Ad DNA-binding proteins to the exterior of IEVs
would solve this issue, with the Ad proteins also acting
in transporting the DNA into the nucleus during
infection.
Localization of cargo to the external surface of EVs
or IEVs would also point at their endosomal origin,
similar to exosomes. Inward budding inside the late
endosomes would result in the outer surface of the
budding intraluminal vesicles (ILVs) being exposed to
the endosomal contents including DNA or Ad proteins
as observed in the case of IEVs, illustrated in Figure 11
for a hypothetical mechanism of IEV formation. This
would be in contrast to the EVs budding from the
plasma membrane, i.e. microvesicles, whose external
surface is continuously exposed to the extracellular
space, while the intravesicular cargo of both EV types
is derived from the cytoplasm. The exosome pathway
of IEV formation with viral cargo on their surface
would require the viral cargo to enter the late endo-
some lumen before ILV budding. This could occur via
autophagocytosis, a known pathway for cells to dispose
of foreign molecules such as cytosolic DNA [63] and
viral proteins, which are recognized by receptors
including cGAS of the STING pathway [64,65] and
other pattern recognition receptor proteins. This sug-
gested process of IEV cargo loading is presented in
Figure 11: the recognition of cytosolic Ad DNA leads
to the formation of autophagosomes [65], which fuse
with late endosomes after maturing, followed by
another fusion with lysosomes for the degradation of
autophagocytosed material [63]. In the case of IEV
secretion, late endosomes forming ILVs would however
fuse with the plasma membrane, releasing the ILVs as
the final step of the exosome secretion pathway. Ad
hexon is known to change in pH 4–5 into a more
lipophilic conformation [66], which could promote its
binding to the intraluminal membrane of late endo-
somes as they are acidic, though Ad hexon has also
been shown to bind phosphatidylcholine in neutral pH
[67]. Ad hexon would thus be able to serve as a linking
protein for other Ad proteins to bind the forming
IEVs. These include Ad DNA binding proteins V,
VIII and X [68], of which at least protein V could be
identified in IEVs in Figure 9a and b in addition to a
clear enrichment of hexon in IEVs compared to their
respective cell lysates. Cargo loading inside the IEVs is
also possible, even though according to our results the
vast majority of Ad DNA is bound to their outer sur-
face. This mechanism would require cargo to bind in
the cytosolic side of late endosomes or plasma mem-
brane in the exosome and microvesicle secretion path-
ways, respectively. Proteins such as Lamp2C have been
shown to be able to bind DNA [69], and given that
Lamp2C is a splice variant of Lamp2, a protein known
to be enriched in EVs, it could mediate the loading of
cytosolic DNA into IEVs and other EVs.
As stated above, IEVs were secreted by living cells
already prior to the lytic release of mature virions and
visible signs of early apoptosis. Based on these observa-
tions, we cannot completely exclude the possibility of a
few individual infected cells dying during the first
24 hours after the initial infection, leading to the gen-
eration of small apoptotic vesicles as a source for the
viral load observed in our results. Alternatively, the
viral cargo could also end up in the cytoplasm of the
cell as a result of a failed infection, and it could be
directed to exocytosis via EVs. However, considering
the gradual increase in the amount of viral DNA in the
A549 IEVs, active secretion of DNA via IEVs by living
infected cells appears to provide a more plausible
explanation. The total viral DNA load associated with
the A549 IEVs at the D1 time point was approximately
20 times lower than at D3 (Figure 9(c)), when the
apoptosis of infected cells had progressed to a clearly
visible level (Figure 3(a)). If the viral DNA would have
been dominantly secreted in apoptotic particles, the
amount of DNA in the IEVs would have been expected
to increase proportionately, as appeared to be the case
with PC-3 cells. As the accompanying increase of Ad
DNA in PC-3 IEVs from D1 to D3 was well over 300-
fold and the DNA secretion stabilized by D5 with the
cells dying, it could be determined together with the
observation that the Ad DNA per particle ratio also
increased (Figure 8(e)), that dying cells release IEVs
with significantly more Ad DNA than living cells.
Compared to the early time point (D1 and D2) IEVs,
in D3 and later samples the DNA was also accompa-
nied by a much higher amount of viral coat protein.
remaining intensity after proteinase K treatment (without Triton X-100) of each individual sample set presented in d. In a–d,
representative blots of two separate experiments are shown. In c and d, only one replicate of A549 D1 samples was analysed, as the
second replicate did not produce a sufficient signal for analysis without proteinase K treatment. Additionally, non-treated PC-3 D1
samples produced a very low signal below the background caused by proteinase K treatment. These samples were estimated at
complete loss of signal based on the similar signal intensities from proteinase K with and without Triton X-100.
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This supports the idea that the portion of IEVs from
dying cells contain a notable load of viral proteins and




Figure 10. Viral DNA is packed differently in IEVs and free virions. (a) The total viral DNA carried by IEVs was measured from pooled
fractions 1–6. A more steadily increasing amount of Ad DNA was found in the IEVs from D1 to D5 in A549 samples, but in PC-3 the
increase happened only between D1 and D3 and then remained unchanged. DNA concentrations were standardized against the
sum of each time point, with individual results and their median presented. (b) To evaluate whether DNA was protected by the IEV
membrane or present externally, pooled IEV fractions 1–6 were treated with proteinase K followed by DNase I to cleave any
extravesicular DNA. The DNA concentration was then measured and compared to the untreated controls and expressed as a ratio of
the remaining DNA after treatment, with individual results presented on a logarithmic scale. Purified Ad was used as a positive
control for the effect of enzyme treatment on the DNA encapsulated in virions and human DNA (GAPDH sequence) was also
measured to control the treatment’s effect on DNA from a non-viral source. Proteinase K treatment was performed at +37°C (circles)
and at +55°C (squares). Only the treatment at +55°C made the DNA from purified virions accessible to degradation by DNase. Ad
genes E4 and E1A from the opposite ends of the viral genome were assessed by qPCR to demonstrate that the whole viral genome
was present in the IEV samples. An almost equal ratio of 1:1 of both genes E4 and E1A was measured for both cell lines, suggesting
that an intact genome was present. In a, N = 3 for all time points. In b, N = 2 for viral control and N = 3 for all of the IEV samples
except for A549 GAPDH, where N = 2 in D1 both conditions and N = 2 in D3 + 55°C due to undetectable concentrations. Statistical
significance in a and b was assessed using paired, two-tailed Student’s t-test. In a, statistical significance between different time
points is denoted by grouping with letters, giving samples with no significant difference the same letters, A549 in lower case and
PC-3 in capitalized. In b, statistical comparison was performed between DNA concentrations obtained with proteinase K treatments
at different temperatures, with asterisks denoting p-values of statistical significance: p < 0.05, **: p < 0.01 and ***: p < 0.001. No
statistically significant differences were found between the amounts of E4 and E1A DNA in any of the samples. p-values of
statistically differing samples are listed in Supplementary Figure 12.
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While some differences were observed in the IEV
preparations between the two different cancer cell
lines, their overall properties were very similar. In
terms of cytotoxicity, the difference between the D1
and later time point PC-3 samples was clearer than in
the A549 samples. This may be explained by the rela-
tively low amount of infected cells at that time point due
to low expression of the CAR receptor [70,71] and
DSG2 [72] in PC-3 cells. The differences in the mole-
cular cargo such as the amounts of hexon, Hsp70, CD9
and CD81 proteins or viral DNA reflected the status of
the cells and seemed to be the major separating factor
between the IEVs from different time points and cEVs.
Regarding the protein markers, D1 IEVs seemed to
correspond to a lag-phase type of IEVs. This is in con-
trast to the other time points, where very little of any of
the studied proteins were present, even though the over-
all protein profiles seemed similar across all time points.
The amount of viral DNA and total proteins also
appeared to correlate with the vesicle density, which
could be explained with proteins and nucleic acids hav-
ing a relatively high density. Additionally, regardless of
infection, the basic morphology of the vesicles remained
the same, suggesting that the IEV secretion may be an
adaptation from the normal EV secretion where viral
molecules are packed in as an additional cargo.
The secretion of IEVs has been suggested by
Takahashi et al. [6] to be a defensive strategy deployed
by the infected cells to rid themselves of the harmful viral
DNA. However, given that the IEVs are able to spread
the infection to other cells, this mechanism could instead
be hypothesized to be an evolutionary trait of the Ad
virus, by which the cell’s natural secretion pathways are
exploited to promote viral dispersal. Ad could spread
from cell to another undetected, as suggested by the
“Trojan horse” theory of EVs and viruses [15], if the
Figure 11. A schematic representation of the IEV loading mechanism in infected cells. After infection of cells, Ad replication results
in the virus DNA and proteins accumulating in the cytoplasm in addition to the nucleus. The viral components are recognized by
receptors in plasma membrane, endosomes and forming phagosomes (1a, b and c). EVs budding off from the plasma membrane
can entrap viral components localized to the inner surface of the plasma membrane, creating microvesicles with intravesicular viral
cargo (2a). Phagosomes fuse with late endosomes (2b), forming endo-phagosomes where the phagosomal contents are released
into the lumen of the endo-phagosome. Endo-phagosomes mature to multivesicular bodies (MVB) (3) where additional inward
budding generates ILVs with viral components in their lumen (4a). Adsorption of viral components, delivered by phagosomes, to
the surface of ILVs generates vesicles with a corona of viral components. MVB contents can be degraded by its fusion with
lysosomes (5a). Alternatively, MVB fusion with the plasma membrane releases ILVs as exosomes, with viral components in their
lumen and on their surface, to the extracellular space (5b).
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EV provides camouflage for the virus. However, our
observation was that the IEVs were affected by the Ad
neutralizing antibodies, suggesting that as such they will
not offer a full cover against the immune response.
Nevertheless, IEVs could be important mediators of the
infection to neighbouring cells that Ad could not nor-
mally enter due to the absence of virus receptors. While
IEVs provide a novel paradigm for virus biology as alter-
native within-host vectors of the viral genome, they might
also prove useful in gene and cancer therapy applications.
In particular, the production of oncolytic IEVs could be
optimized in healthy, non-cancerous cells, for a safe for-
mulation of viruses for intravenous cancer treatment, if
they can be effectively hidden from the immune system.
Materials and methods
Cell culture
A549 and PC-3 cells were acquired from the American
type Culture Collection and maintained in Ham’s F12k
base medium (ThermoFisher Scientific, Massachusetts,
USA) supplemented with 10% (v/v) FBS (Gibco,) and
100 units/mL penicillin and 100 µg/mL streptomycin
(Gibco, ThermoFisher Scientific), in a 5% CO2 + 37°C
environment. Growth medium used for EV/IEV pro-
duction was prepared with 10% FBS and ultracentri-
fuged overnight with 110,000 g at +4°C with Optima
LE-80 K ultracentrifuge (Beckman Coulter, Brea, CA,
USA), rotor SW32Ti (Beckman Coulter), in order to
remove any FBS-derived EVs. This EV-free medium
was diluted to a final concentration of 5% FBS and
changed to cell cultures when they reached approxi-
mately 70% confluence. For infecting the cells to
induce IEV production, the medium was also supple-
mented with Ad5/3-D24-GMCSF viruses at a concen-
tration of approximately 30 particles per cell according
to NTA.
EV and IEV isolation
cEVs were collected from the CCM after three days
of culture, while the medium from infected cells was
collected either after five days of uninterrupted incu-
bation or every 24 hours for five days after the initial
infection (D1–D5 samples), replacing the collected
medium with fresh, virus-free medium. Cells were
removed by pelleting them first by centrifugation
with 500 g at +4°C for 10 minutes and the resulting
supernatant was collected for the isolation of EVs
and IEVs.
Iodixanol density gradient centrifugation
IEVs/EVs were purified in a continuous density gradi-
ent prepared with iodixanol (Optiprep©, Sigma
Aldrich, St. Louis, MO, USA) diluted in DPBS contain-
ing 2 mM MgCl2. Following the removal of cells, any
remaining debris was removed from the CCM by addi-
tional centrifugation with 15,000 g at +4°C for 15 min-
utes with rotor SW32Ti. The EVs/IEVs were then
concentrated from the supernatant by ultracentrifuga-
tion at 150,000 g at +4°C for two hours with 200 µL of
45% iodixanol added to the bottom of the centrifuge
tube to act as a density cushion. The bottom 3 mL of
the supernatant containing the vesicles was then con-
centrated further to 250 µL by ultrafiltration with
Amicon Ultra-15 10 kDa centrifugal ultrafiltration
units (MerckMillipore, Burlington, MA, USA) and
mixed with 750 µL of 60% iodixanol for bottom-load-
ing of the samples into the following density gradient.
The density gradient was prepared with the diffu-
sion method in a 13.5 mL ultracentrifuge tube by over-
laying 4 mL of 45% iodixanol with 4 mL of 25%
iodixanol and filling the rest of the tube with DPBS-2
mM MgCl2. The tubes were sealed with parafilm, care-
fully tipped to a horizontal position and incubated for
one hour at RT. After the incubation, the tubes were
chilled on ice and 1.5 mL were removed from the top
to make room for sample loading. The samples mixed
with iodixanol were then loaded through the gradient
to the bottom of the tube with a long-nosed glass
Pasteur pipette and ultracentrigued at 200,000 g at
+4°C for three hours with rotor SW41Ti (Beckman
Coulter). After the run 1 mL fractions were collected
from the top of the tubes for further analyses, measur-
ing their densities gravimetrically.
Isolation of oncolytic adenoviruses
Ad5/3-D24-GMCSF viral particles were isolated from
the dead, infected A549 and PC-3 cells using the iodix-
anol density gradient based protocol described by Peng
et al. [73]. Briefly, the washed, pelleted cells were lysed
by four freeze–thaw cycles and the cellular debris was
removed by centrifugation with 5000 g at +4°C for
10 minutes. The gradient was prepared into a
13.5 mL ultracentrifuge tube by layering 2 mL of
40%, 3 mL of 25% and 4 mL of 15% iodixanol diluted
in DPBS containing 2 mM MgCl2, with the 15% solu-
tion containing additional 1 M NaCl. Rest of the tube
was filled with the clarified virus-containing cell super-
natant and ultracentrifuged at 200,000 g at +4°C for
two hours with rotor SW41Ti. The resulting band of
viruses just below the 40% and 25% iodixanol inter-
phase was collected and iodixanol was removed by
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serial ultrafiltration with DPBS, using Amicon Ultra-4
10 kDa ultrafiltration units at +4°C. The size distribu-
tion and particle concentrations of the virus prepara-
tions was determined with NTA from a heat-
inactivated samples incubated at 95°C for 15 minutes.
NTA analysis
The particle concentrations and size distributions of
the samples were determined using Nanosight LM-14
instrument equipped with a 405 nm, 60 mW laser
(Nanosight, Salisbury, Great Britain) and SCMOS cam-
era (Hamamatsu Photonics K.K., Hamamatsu, Japan).
The camera level was adjusted to 15 and measurement
time to 60 s. The results were analysed using
NanoSight NTA software v3.0., with detection thresh-
old set to 5. Potentially infective samples were inacti-
vated by heating at +95°C for 15 minutes prior to
measurement.
Total protein assay
Total protein concentration of samples was measured
with Pierce BCA protein assay kit (ThermoFisher
Scientific) as instructed by the manufacturer.
Background signal caused by sucrose or iodixanol in
the EV/IEV preparations was subtracted by measuring
corresponding blank samples of gradient medium.
Viability assay of EV/IEV preparations
Cell viability was assessed with AlamarBlue viability
assay (ThermoFisher Scientific) as instructed by the
manufacturer. Cells were seeded on a 96-well plate at
a density of 5000 cells per well in 100 µL of culture
medium containing 5% FBS and allowed to attach for
one day in the cell incubator. The following day, equal
volumes (1–10 µL) of each collected EV/IEV or corre-
sponding blank sucrose or iodixanol fraction was
added to the cells and they were incubated for
72 hours. Following the incubation, 10 µL of
AlamarBlue reagent was added to each well, the plates
were incubated for one to three hours and fluorescence
intensities were measured with Varioskan LUX
(ThermoFisher Scientific) microplate reader with exci-
tation at 570 nm and emission at 585 nm. Background
signal was assessed with cell free wells and the results
were compared to non-treated cells, representing 100%
viability.
Treatment of IEVs with Ad neutralizing antibody
Eight microlitres of IEV fractions 4–6 were pooled
from D1, D3 and D5 for a total volume of 24 µL
each, of which 12 µL was mixed with 1 µL of rabbit
anti-Adenovirus type 5 antibody (ab6982, Abcam) and
the other 12 µL was mixed with 1 µL of DPBS and
retained as non-treated control. The samples were
incubated for 1 h at room temperature and divided to
three wells on a 96-well plate prepared the previous day
with 5000 cells per well. The cytotoxic effect of the
samples was then assessed with AlamarBlue viability
assay after 72 hours as described above.
Detergent treatment of IEVs and Ad
Ten microlitres of IEV fractions 4–6 were pooled from
D1, D3 and D5 for a total volume of 30 µL each, of
which 15 µL was retained as non-treated controls and
the other 15 µL was mixed with 1 mL of 0.1% (w/v) of
Triton X-100. For free Ad controls, 5E8 and 5E9 par-
ticles were used for both non-treated and Triton X-100
treated samples. The Triton X-100 samples were loaded
on top of 10.5 mL of 25% iodixanol-DPBS in 13.5 mL
ultracentrifuge tubes and ultracentrifuged at 200,000 g
at +4°C for two hours with rotor SW41Ti. The super-
natant was aspirated, the pellets were collected in
approximately 40 µL of residual supernatant. The sam-
ples and their non-treated controls were then divided
to three wells on a 96-well plate prepared the previous
day with 5000 cells per well, mock controls were trea-
ted with an equal amount of 25% iodixanol-DPBS. The
cytotoxic effect of the samples was then assessed with
AlamarBlue viability assay after 72 hours as described
above.
Preparation of cell lysates
Cell lysates were prepared with cell cultures prior to viral
infection and every 24 hours after the initial infection.
The culture medium containing floating cells was col-
lected and the adherent cells were washed with ice cold
DPBS, which was also collected. The cells were collected
by centrifugation at 500 g at +4°C for 10 minutes and
washed once with ice cold DPBS. Adherent cells were
lysed with RIPA buffer (Sigma Aldrich) supplemented
with Protease inhibitor cocktail (Sigma Aldrich), scraped
and added to the pellet of floating cells. The cells were
incubated for 30 minutes at +4°C and centrifuged with
16,000 g for 20 minutes at +4°C, collecting the super-
natant and discarding the pellet.
JOURNAL OF EXTRACELLULAR VESICLES 19
SDS-PAGE and Western blot
Using 0.9 mL of each fraction, fractions 1–6 were
pooled representing IEVs and cEVs, with fractions 7–
10 representing the impurities. Iodixanol was removed
by serial ultrafiltration, using Amicon Ultra-4 10 kDa
ultrafiltration units at +4°C, after diluting the samples
with DPBS to a total volume of 40 mL. The samples
were filtered down to a volume of approximately
500 µL, diluted with 10 mL of DPBS and filtered once
more down to 500 µL. SDS was added to a final con-
centration of 0.1% (w/v) to reduce sample loss due to
adsorption to the filter unit prior to collection.
Sample amounts were standardized by total protein
assay as described above and prepared with denaturing
Laemmli sample buffer in +95°C. For stain-free ima-
ging, the proteins were separated with SDS-PAGE on a
10% Mini-PROTEAN® TGX-Stain free™ Precast Protein
Gel (BioRad, Hercules, CA, USA) and imaged with
Chemidoc™ MP imaging system (BioRad) using the
stain-free UV illumination protocol. For western blot-
ting, the proteins were separated with SDS-PAGE on a
4–20% TGX-Stain free™ Precast Protein Gel (BioRad)
and transferred to a polyvinylidene fluoride membrane.
The membrane was blocked with 5% (w/v) bovine
serum albumin (BSA) in Tris buffered saline-0.1% (v/
v) Tween-20 (TBS-T) for one hour at room tempera-
ture and cut to strips corresponding to the weight of
proteins to be analysed. Each strip was then incubated
with primary antibodies diluted in 5% BSA-TBS-T
(mouse anti-TSG101 (51/TSG101, 1:500, reducing con-
ditions, BD Biosciences, Frankling Lakes, NJ, USA),
mouse anti-Hsp70 (7/Hsp70, 1:500, reducing condi-
tions, BD Biosciences), mouse anti-CD9 (HBM-CD9,
1:1000, non-reducing conditions, HansaBioMed Life
Sciences, Tallinn, Estonia), mouse anti-CD81 (HBM-
CD81-EM4, 1:500, non-reducing conditions,
HansaBioMed Life Sciences), mouse anti-α-tubulin
(DM1A, 1:500, reducing conditions, Sigma Aldrich),
rabbit anti-GM130 (NBP1-89756, 1:250, reducing con-
ditions, Novus Biologicals, Centennial, Colorado,
USA), rabbit anti-Adenovirus type 5 antibody
(ab6982, 1:4000, non-reducing conditions, Abcam))
overnight at +4°C. The strips were then washed with
TBS-T and incubated with secondary antibody-HRP
(ECL™ Anti-mouse IgG, 1:4000, GE healthcare, Little
Chalfont, UK) or goat anti-rabbit IgG (G-21234
1:10,000, ThermoFischer Scientific) in TBS-T for one
hour at room temperature. The strips were washed
with TBS-T and briefly with TBS, incubated for
5 min in ECL substrate (Clarity™ Western ECL
Substrate, BioRad) and imaged with BioSpectrum®
imaging system (Ultra-Violet Products, Cambridge,
UK). Image processing and signal intensity was
assessed with imageJ software.
Dot blot analysis
Two microlitres of each density gradient fraction was
blotted directly onto a nitrocellulose membrane and
allowed to dry. For assessing Ad protein topology on
IEVs, 16 µL of each sample was treated at +55°C for
1 hour with 2 µL of proteinase K (20 µg/µL)
(ThermoFischer Scientific) + 2 µL of DPBS or 2 µL of
2% (w/v) Triton X-100, while 4 µL of only DPBS was
added to control samples, followed by 15 min incuba-
tion at +95°C for enzyme inactivation. Low concentra-
tion samples were applied up to 5 times on the
membrane to increase signal intensity. The membranes
were then blocked with 5% (w/v) BSA in TBS-T for one
hour at room temperature, followed by overnight incu-
bation at +4°C with the primary antibody (mouse
monoclonal anti-Ad hexon protein antibody 8C4,
1:2000, Abcam, or rabbit polyclonal anti-Adenovirus
type 5 antibody ab6982, 1:4000) and detection with
secondary antibody-HRP as described above.
qPCR analysis of viral DNA
DNA extraction and analysis
gDNA was extracted using NucleoSpin Tissue kit
(Macharey-Nagel, Düren, Germany) according to the
manufacturer protocol (support protocol (6.5) for
gDNA and viral DNA from blood samples). The
volumes used for extraction were 200 µL for individual
fractions and 150 µL for pooled fractions 1–6 of iodix-
anol purified samples or 100 µL of individual fractions
of sucrose purified samples. qPCR was performed using
Maxima Probe/ROX qPCR Master Mix (ThermoFisher
Scientific) and LightCycler480 system (Roche, Basel,
Switzerland) with following cycling conditions: +95°C
for 10 min, 50 cycles of (+95°C for 15 s, +60°C for
1 min). Equal volume of gDNA was used as a template
in qPCR, sequences for primers and probes for Ad E4
and E1A were adapted from previous publications
[38,74].
Primers:
Proteinase K and DNAse treatments
In order to examine whether the DNA was inside IEVs,
100 µL of pooled fractions 1–6 were treated with pro-
teinase K to free any DNA inside virus capsid, followed
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by degradation with DNAse I. A sample of purified free
virus was used as a control for the treatment. Samples
were either first incubated at +55°C with pH adjusted
to 4 with 50 mM NaAc and HCl for 30 min, followed
by neutralizing pH with NaOH and treatment with
1 mg/ml proteinase K (ThermoFisher Scientific) for
1 h at +37°C, or directly treated with proteinase K at
+55°C. Proteinase K was inactivated with 5 mM PMSF
for 1 h at +37°C, followed by addition of 5 U of DNase
I (ThermoFisher Scientific) and incubation for 1 h at
+37°C. Treatment was ended by addition of 1:10
volume of EDTA and incubation of 10 min in +65°C.
The samples were then used for gDNA extraction as
described above.
Fluorescence microscopy of infected cells
Apoptosis assay with Hoechst 33342 and propidium
iodide (PI) staining
Cells were seeded in the wells of a 12 well plate and
infected as described above. Every 24 hours following
the initial infection the cells were stained with 100 µg/
mL of both Hoechst 33342 (ThermoFisher Scientific)
and PI (ThermoFisher Scientific), centrifuged with
1000 g for 5 minutes and inspected with EVOS FL
Imaging System using DAPI and RFP light cubes.
Immunofluorescence staining of Ad hexon coat
protein
Cells were seeded in the wells of a 6 well plate and
infected as described above. Every 24 hours following
the initial infection the cells were washed with DPBS
and fixed with 4% (w/v) paraformaldehyde for 10 min-
utes at room temperature. The cells were washed with
DPBS and permeabilized with 0.1% (v/v) Triton X-100
for 10 minutes, washed three times and blocked in 5%
BSA-TBS-T for one hour at room temperature, fol-
lowed by incubation with anti-Ad hexon protein anti-
body in 5% BSA-TBS-T (1:2000) overnight at +4°C.
After incubation, the cells were washed three times
with TBS-T and incubated with goat anti-mouse IgG-
Alexa Fluor 488 secondary antibody (ThermoFisher
Scientific, 1:200) in 5% BSA-TBS-T for one hour at
room temperature, washed with TBS-T three times
and incubated with 1 µg/mL of DAPI (ThermoFisher
Scientific) for one minute. The cells were washed with
TBS and inspected with EVOS FL Imaging System
using DAPI and GFP light cubes. Negative controls
were prepared with non-infected cells with the com-
plete staining protocol for non-specific binding and
infected cells without staining for auto fluorescence
background.
TEM of IEV-treated cells
Two lakh cells were seeded on top of EM grade 0.1 mm
coverslips in 6 well plates and on the following day
they were treated with 10 µL of IEV fraction 4 obtained
with iodixanol density gradient. After one or two days
of incubation the cells were fixed with 2% (v/v) glutar-
aldehyde for 20 minutes at room temperature. The cells
were washed two times with 0.1 M Na-phosphate buf-
fer pH 7.0 and osmicated with 1% OsO4 in 0.1 M
NaCac buffer for 1 h at RT. The samples were washed
and dehydrated with ethanol, dipped in acetone and
covered with Epon for 2 h at RT and 18 h at +60°C.
Sixty nanometres sections were cut from the samples
onto pioloform grids and post-stained with 0.5% ura-
nyl acetate for 30 min and 3% lead acetate for 1 min.
Imaging was performed with Jeol JEM 1400 electron
microscope (Akishima, Tokyo, Japan) operated at
80 kV.
Cryo-TEM of EV-/IEV-samples
Iodixanol or sucrose was removed by extensive ultra-
filtration with Amicon Ultra-0.5 10 kDa ultrafiltration
units from fresh, non-frozen samples collected five
days after infection of the cells as described above.
The 15,000 g pellets from D5 were collected with
100 µL of DPBS and washed by centrifuging three
times with 10,000 g for 5 min at +4°C in 1 mL of
DPBS. The vitrified samples were prepared with a
Leica EM GP vitrification device from 3 μL aliquots
of each sample on freshly glow-discharged Quantifoil
R2/2 grids (Quantifoil, Großlöbichau, Germany). The
Gene Forward Reverse Probe
Adenovirus E4 5′-GGAGTGCGCCGAGACAAC-3′ 5′-ACTACGTCCGGCGTTCCAT-3′ 5′-TGGCATGACACTACGACCAACACGATCT-3′
Adenovirus E1A 5′-AACCAGTTGCCGTGAGAGTTG-3′ 5-CTCGTTAAGCAAGTCCTCGATACA-3′ 5′-CACAGCCTGGCGACGCCCA-3′
Human GAPDH 5ʹ-GGTCACGTGTCGCAGAG-3’ 5ʹ-CATTCATTTCCTTCCCGGTTG-3’ 5ʹ-TGCATCCCTGTCCGGATGCT-3’
DNA concentrations (in arbitrary units) for comparative analyses were then calculated from the acquired Ct-values with the formula
DNA½ ¼2Ct;
and used to compare paired samples.
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samples were observed in a FEI Talos Arctica micro-
scope (ThermoFisher Scientific) operated at 200 kV.
The images were recorded at a magnification of
57,000× with a FEI Falcon 3 camera operated in linear
mode in the Instruct-FI and Biocenter Finland cryoEM
unit, University of Helsinki.
Statistical analysis
Statistical analysis was performed with SPSS software
version 22.0 using Student’s two-tailed paired t-test or
one-way ANOVA with Tukey’s HSD post hoc analysis,
when comparing large sets of density gradient fractions.
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